Ancora Advisors LLC Purchases 33,296 Shares of The Cooper Companies, Inc. $COO

Ancora Advisors LLC raised its holdings in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 35,421.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,390 shares of the medical device company's stock after buying an additional 33,296 shares during the quarter. Ancora Advisors LLC's holdings in Cooper Companies were worth $2,394,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Avalon Trust Co acquired a new stake in Cooper Companies in the 2nd quarter valued at $25,000. Root Financial Partners LLC boosted its position in Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company's stock valued at $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. grew its stake in Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company's stock worth $26,000 after buying an additional 187 shares during the last quarter. Elevation Wealth Partners LLC grew its stake in Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company's stock worth $29,000 after buying an additional 375 shares during the last quarter. Finally, J.Safra Asset Management Corp acquired a new position in shares of Cooper Companies in the 2nd quarter worth approximately $32,000. Institutional investors own 24.39% of the company's stock.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: A Seeking Alpha analysis argues that improving cash conversion and “strategic optionality” could support a valuation re-rating for Cooper Companies. The thesis suggests investors may increasingly value the company’s ability to generate cash and pursue growth or capital-allocation opportunities. Cooper Companies: Cash Conversion And Strategic Optionality Create A Re-Rating Setup
• Positive Sentiment: The company’s latest reported quarter showed solid operating momentum: earnings per share of $1.21 exceeded the $1.10 consensus estimate, while revenue of $1.08 billion topped expectations of $1.05 billion and increased 7.9% year over year. Management maintained fiscal 2026 EPS guidance of $4.58-$4.66, supporting the bullish earnings narrative.
• Neutral Sentiment: Investors are looking ahead to Cooper Companies’ scheduled quarterly earnings release, which is the next near-term catalyst identified in recent coverage. The report will be important for confirming demand trends, margins, cash conversion and whether full-year guidance remains achievable. Cooper Companies Projected to Post Quarterly Earnings
• Negative Sentiment: Valuation remains a risk: COO trades at a high earnings multiple relative to its growth rate, meaning any earnings miss, weaker guidance or slowing revenue growth could pressure the shares. The stock also remains below its 50-day moving average, indicating that near-term momentum has not fully recovered.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $69.73 on Thursday. The Cooper Companies, Inc. has a 52 week low of $58.89 and a 52 week high of $89.83. The firm has a fifty day moving average of $72.74 and a two-hundred day moving average of $70.55. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The stock has a market capitalization of $13.60 billion, a price-to-earnings ratio of 59.09, a PEG ratio of 1.81 and a beta of 0.82.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.11. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company earned $0.96 EPS. The company's revenue for the quarter was up 7.9% compared to the same quarter last year. As a group, equities research analysts predict that The Cooper Companies, Inc. will post 4.63 EPS for the current year.

Wall Street Analyst Weigh In

COO has been the topic of a number of research analyst reports. BNP Paribas Exane decreased their price target on Cooper Companies from $95.00 to $92.00 and set an "outperform" rating on the stock in a research report on Monday, June 8th. Wall Street Zen upgraded shares of Cooper Companies from a "hold" rating to a "buy" rating in a research report on Sunday, June 21st. JPMorgan Chase & Co. dropped their target price on shares of Cooper Companies from $80.00 to $71.00 and set a "neutral" rating for the company in a research note on Friday, June 5th. KeyCorp reiterated a "sector weight" rating on shares of Cooper Companies in a research report on Friday, June 5th. Finally, UBS Group started coverage on Cooper Companies in a research report on Tuesday, July 28th. They set a "neutral" rating and a $75.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Cooper Companies presently has an average rating of "Hold" and an average price target of $81.64.

Cooper Companies Profile

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source